Previous Article | Next Article 
Molecular and Cellular Biology, June 1999, p. 4255-4261, Vol. 19, No. 6
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
RNA Polymerase III Transcription Factor IIIB Is a
Target for Repression by Pocket Proteins p107 and p130
Josephine E.
Sutcliffe,
Carol
A.
Cairns,
Angela
McLees,
Simon J.
Allison,
Kerrie
Tosh, and
Robert J.
White*
Institute of Biomedical and Life Sciences,
Division of Biochemistry and Molecular Biology, University of
Glasgow, Glasgow G12 8QQ, United Kingdom
Received 21 December 1998/Returned for modification 28 January
1999/Accepted 22 March 1999
 |
ABSTRACT |
RNA polymerase III (Pol III) transcription is subject to repression
by the retinoblastoma protein RB, both in vitro and in vivo (R. J. White, D. Trouche, K. Martin, S. P. Jackson, and T. Kouzarides,
Nature 382:88-90, 1996). This is achieved through a direct interaction
between RB and TFIIIB, a multisubunit factor that is required for the
expression of all Pol III templates (C. G. C. Larminie,
C. A. Cairns, R. Mital, K. Martin, T. Kouzarides, S. P. Jackson, and R. J. White, EMBO J. 16:2061-2071, 1997; W.-M. Chu,
Z. Wang, R. G. Roeder, and C. W. Schmid, J. Biol. Chem.
272:14755-14761, 1997). p107 and p130 are two closely related proteins
that display 30 to 35% identity with the RB polypeptide and share some
of its functions. We show that p107 and p130 can both repress Pol III transcription in transient transfection assays or when added to cell
extracts. Pull-down assays and immunoprecipitations using recombinant
components demonstrate that a subunit of TFIIIB interacts physically
with p107 and p130. In addition, endogenous TFIIIB is shown by
cofractionation and coimmunoprecipitation to associate stably with both
p107 and p130. Disruption of this interaction in vivo by using the E7
oncoprotein of human papillomavirus results in a marked increase in Pol
III transcription. Pol III activity is also deregulated in fibroblasts
derived from p107 p130 double knockout mice. We conclude that TFIIIB is
targeted for repression not only by RB but also by its relatives p107
and p130.
 |
INTRODUCTION |
The retinoblastoma protein RB has
two close relatives, called p107 and p130, to which it is 30 to 35%
identical (reviewed in references 13 and
27). These three are often referred to as the pocket
proteins, because most of their homology lies within a bipartite region
called the pocket domain. They can each inhibit cell growth and
proliferation when overexpressed in tumor cells, an effect that is
associated with G1-specific cell cycle arrest (7, 30,
44, 45). A number of common target proteins have been found to
interact with the pocket domains of RB, p107 and p130, including
members of the E2F family of cellular transcription factors and the
oncoprotein products of several DNA tumor viruses (reviewed in
references 10, 15, 27, and 36).
As a consequence, there is significant redundancy between the various
pocket proteins. This is particularly marked for p107 and p130, which
are much more closely related to each other (~50% amino acid
identity) than they are to RB (30 to 35% identity). A clear
demonstration of the redundancy between p107 and p130 was provided by
the phenotypes of knockout mice. Thus, animals lacking either p107 or
p130 develop normally, whereas animals lacking both of these pocket
proteins die within hours of being born (8). In contrast,
Rb
/
mice die at midgestation, displaying
defects in both proliferation and differentiation of certain cell
lineages (6, 17, 23). This suggests that at least some
functions of RB cannot be performed by p107 or p130. This contention is
supported by the fact that many tumors contain mutations in
Rb, whereas the genes encoding p107 and p130 are not
targeted for inactivation in cancers.
One of the functions of RB that has been demonstrated relatively
recently is the regulation of RNA polymerase (Pol) III transcription (reviewed in references 21 and
39). The synthesis of tRNA and 5S rRNA by Pol III in
vivo was found to be fivefold more active in primary fibroblasts from
Rb
/
mice than in the corresponding cells
from Rb+/+ mice (43). Furthermore,
recombinant RB will inhibit the transcription of a range of Pol III
templates both in vitro and in transfected cells (5, 22,
43). These effects can be explained by the ability of RB to bind
and inactivate a general Pol III factor called TFIIIB (5,
22). Immunoprecipitation and pull-down experiments demonstrated a
physical interaction between recombinant RB and TFIIIB (5,
22). Furthermore, a stable association between endogenous RB and
TFIIIB was shown by cofractionation and coimmunoprecipitation (5,
22). Substitutions in RB that prevent it from binding to TFIIIB
also prevent it from repressing Pol III transcription (5).
Functional assays with purified factors confirmed that TFIIIB is
inactivated specifically by its interaction with RB (5, 22).
TFIIIB is a multisubunit complex that includes the TATA-binding protein
(TBP) and an essential subunit called BRF (reviewed in references
14, 31, and 40). It is required
for the expression of all class III genes, serving to recruit Pol III
to a promoter and position it over the initiation site (18).
This recruitment involves an interaction between BRF and Pol III
(19, 38). The ability of RB to target TFIIIB provides it
with the opportunity to regulate all Pol III-transcribed genes. This
can be expected to have a major effect upon nuclear activity.
Since the three pocket proteins share a number of functions, it was
important to determine whether p107 and p130 are also able to regulate
Pol III transcription. A combination of in vitro and in vivo
experiments indicate that this is the case. Recombinant p107 and p130
will both bind to TFIIIB and repress a variety of class III genes in
cell extracts and in transfected cells. Furthermore, endogenous p107
and p130 can be shown by cofractionation and coimmunoprecipitation analyses to associate stably with endogenous TFIIIB. Specific inactivation of these pocket proteins by using the E7 oncoprotein of
human papillomavirus will stimulate Pol III transcription in vivo. In
addition, Northern blot analysis shows that Pol III activity is
deregulated in fibroblasts derived from
p107
/
p130
/
double knockout mice. We conclude that p107 and p130 share with RB the
ability to bind and repress the general Pol III factor TFIIIB.
 |
MATERIALS AND METHODS |
Cell culture and transfection.
Embryonic fibroblasts (MEFs)
derived from p107+/
p130+/
and p107
/
p130
/
mice were cultured in Dulbecco's
modified Eagle medium (DMEM) with 10% fetal calf serum, as described
previously (16). MEFs were made quiescent by culture in DMEM
containing 0.5% fetal calf serum. The human osteosarcoma cell line
SAOS2 and the murine fibroblast line NIH 3T3 were cultured in DMEM with
10% fetal calf serum, as described previously (20, 45).
Cell lines were transiently transfected by the calcium-phosphate
precipitation method. DNA precipitates were left on the plates
overnight, and then the cells were washed with phosphate-buffered
saline and cultured for 24 h before being harvested. Total RNA was
extracted with TRI reagent (Sigma), according to the manufacturer's
instructions. It was then analyzed by primer extension with both
VAI-specific (5'-CACGCGGGCGGTAACCGCATG-3') and
chloramphenicol acetyltransferase (CAT)-specific
(5'-CGATGCCATTGGGATATATCA-3') labelled primers. Primer
extension reactions were conducted as previously described
(43).
Northern blotting.
Total cellular RNA was extracted by using
TRI reagent (Sigma), according to the manufacturer's instructions.
Agarose gel electrophoresis, Northern transfer, and hybridization were
carried out as described previously (3). The B2 gene probe
was a 240-bp EcoRI-PstI fragment from pTB14. The
acidic ribosomal phosphoprotein (ARPP) P0 probe was a 1-kb
EcoRI-HindIII fragment from the mouse cDNA
(16).
Plasmids.
The pVAI, pHu5S3.1, and pGlu6 plasmids contain the
adenovirus VAI gene, a human 5S rRNA gene, and a human
tRNAGlu6 gene, respectively, and have been described by
White et al. (41). Plasmid pTB14 contains a mouse B2 gene
(42). pCMV-p107 and pCMV-p130 contain full-length p107 and
p130, respectively, in the pCDNA3 vector (45). pCMV-RB
22
contains a null mutant version of full-length RB, in which exon 22 is
deleted, in the pCDNA3 vector (30). pCAT (Promega) contains
the CAT gene driven by the simian virus 40 promoter and enhancer.
Expression constructs encoding the E7 oncoprotein of human
papillomavirus type 16 and its mutant derivatives
21-35 and GLY26
have been described previously (20).
Preparation of extracts and protein fractions.
Glutathione
S-transferase (GST) fusion proteins were expressed in
bacteria and purified on glutathione-agarose as described previously
(22). GST-p107 contains residues 249 to 936 of p107, and
GST-p130 contains residues 372 to 1139 of p130 (9).
Whole-cell extracts were prepared from exponentially growing cells
according to the method of Manley et al. (25). Nuclear extracts were purchased from the Computer Cell Culture Center (Mons,
Belgium). PC-B is the 0.1 to 0.35 M KCl step fraction from a
phosphocellulose column and contains both TFIIIB and Pol III (32). PC-C is the 0.35 to 0.6 M KCl step fraction from a
phosphocellulose column and contains both TFIIIC and Pol III
(32). QS-PC-B contains TFIIIB that has been fractionated by
gradient chromatography on Q-Sepharose followed by phosphocellulose
step chromatography, as described previously (3). DNA
affinity purification of TFIIIC was carried out by applying a PC-C
fraction to a B-block oligonucleotide resin, as described previously
(41). A25(0.15) contains TFIIIB, and A25(1.0) contains Pol
III; both were prepared by applying a PC-B fraction to DEAE-Sephadex,
as described previously (41). The CHep-1.0 fraction contains
TFIIIC that has been prepared by heparin-Sepharose chromatography of a
PC-C fraction, as described previously (41). Gradient
chromatography of a PC-B fraction on heparin-Sepharose was carried out
as described previously (22).
Transcription assays.
Transcription reactions were carried
out as described previously (42), except that pBR322 was not
included and the incubations were for 60 min at 30°C. Radiolabelled
transcripts were resolved on 7% polyacrylamide sequencing gels and
detected by autoradiography.
Pull-down assays.
Reticulocyte lysate (Promega) was used to
synthesize BRF in the presence of [35S]Met and
[35S]Cys, according to the manufacturer's
specifications. Lysate (20 µl) was then incubated at 4°C on an
orbital shaker with 20 µl of glutathione-agarose beads carrying
equivalent amounts (as estimated by Coomassie blue staining) of
immobilized GST, GST-RB, GST-p107, or GST-p130. After 3 h, the
samples were pelleted, supernatants were removed, and the beads were
washed five times with 700 µl of LDB buffer (20 mM HEPES-KOH [pH
7.9], 17% glycerol, 100 mM KCl, 12 mM MgCl2, 0.1 mM EDTA,
2 mM dithiothreitol). Material that remained bound to the beads was
then analyzed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and autoradiography.
Immunoprecipitation.
Whole-cell extract (150 µg) was
incubated at 4°C on an orbital shaker with 20 µl of protein
A-Sepharose beads carrying equivalent amounts of prebound
immunoglobulin G. Samples were then pelleted, supernatants were
removed, and the beads were washed five times with 150 µl of LDB
buffer. The bound material was analyzed by Western blotting. In the
experiment shown in Fig. 4, reticulocyte lysate (15 µl) containing
BRF translated in the presence of [35S]Met and
[35S]Cys was mixed with nuclear extract (150 µg) during
immunoprecipitation. In this case, the precipitated material was
analyzed by autoradiography rather than Western blotting.
Antibodies and Western blotting.
The antibodies used in this
study were C-15 (Santa Cruz) and G99-549 (Pharminogen) against RB, SD9
(Santa Cruz) and C-18 (Santa Cruz) against p107, anti-Rb2 (Transduction
Laboratories) and C-20 (Santa Cruz) against p130, M-19 (Santa Cruz)
against TAFI48, 128 against BRF (2, 3), and Ab2
against TFIIIC
(33). Western immunoblot analysis was
performed as previously described (41).
 |
RESULTS |
The pocket proteins p107 and p130 inhibit Pol III transcription in
transfected cells.
In order to examine whether p107 and p130 can
inhibit Pol III transcription in vivo, the human osteosarcoma cell line
SAOS2 was transfected with expression vectors encoding these pocket proteins. Primer extension analysis was used to determine the levels of
transcription of a cotransfected VAI gene, which is used as
a Pol III reporter. A control plasmid in which the CAT gene is driven
by the simian virus 40 early promoter was also included in order to
normalize for transfection efficiency. After correction for CAT RNA
levels, p107 and p130 were found to repress VAI expression
by three- to fourfold. This effect is specific, since no repression was
obtained by using an RB null mutant (
22), from which the pocket
region encoded by exon 22 had been deleted (Fig.
1). Similar results were obtained in
transfections using the C33A human cervical carcinoma cell line, where
VAI was again repressed by p107 and p130, but not by the RB
22 mutant (4). We conclude that the RB-related pocket
proteins p107 and p130 can inhibit Pol III transcription in vivo.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 1.
Overexpression of p107 and p130 inhibits Pol III
transcription in vivo. SAOS2 cells were transfected with
pVAI (0.5 µg), pCAT (4 µg), and pCDNA3 vector (2 µg
in lane 1, 1.5 µg in lanes 2 and 5), pCMV-p107 (0.5 µg in lane 2, 2 µg in lane 3), pCMV-RB 22 (2 µg in lane 4), or pCMV-p130 (0.5 µg in lane 5, 2 µg in lane 6). VAI and CAT RNA levels
were assayed by primer extension and then quantitated by using a
phosphorimager. The values shown for VAI have been
normalized to the levels of CAT to correct for transfection efficiency
and are expressed relative to the value obtained for the pCDNA3 control
(arbitrarily designated 100%).
|
|
Recombinant p107 and p130 inhibit Pol III transcription in
vitro.
p107 and p130 were expressed in bacteria as fusions with
GST and then purified by using glutathione-agarose beads. When added to
cell extracts, these fusion proteins were found to inhibit the
transcription of a range of Pol III templates (Fig.
2). For example, GST-p107 and GST-p130
both repressed VAI (Fig. 2A), tRNA (Fig. 2B), and 5S rRNA
(Fig. 2C) genes by two- to fourfold relative to levels of expression
obtained in the presence of an equal amount of GST alone. This response
is comparable with that obtained in vivo (Fig. 1). In addition to these
templates, p107 and p130 fusion proteins were also found to inhibit
expression of Alu and U6 snRNA genes (4). We conclude that
these pocket proteins can serve as general repressors of Pol III
transcription.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Recombinant p107 and p130 inhibit transcription of a
range of Pol III templates in vitro. (A) pVAI template (VA
[250 ng]) was transcribed by using 10 µg of HeLa cell extract that
had been preincubated for 15 min at 30°C with 250 ng of GST (lanes 1 and 3), GST-p107 (lane 2), or GST-p130 (lane 4). (B) pGlu6 template
(250 ng) was transcribed by using 10 µg of HeLa cell extract that had
been preincubated for 15 min at 30°C with 250 ng of GST (lanes 1 and
3), GST-p107 (lane 2), or GST-p130 (lane 4). The cluster of bands
obtained reflects processing of the primary tRNA transcript. (C)
pHu5S3.1 template (250 ng) was transcribed by using 10 µg of HeLa
cell extract that had been preincubated for 15 min at 30°C with 250 ng of GST (lanes 1 and 3), GST-p107 (lane 2), or GST-p130 (lane 4).
|
|
Recombinant p107 and p130 interact with the BRF subunit of
TFIIIB.
RB has been shown previously to associate with TFIIIB to
form a stable complex that includes BRF (5, 22). To test
whether the same is true of p107 and p130, these pocket proteins were expressed as GST fusions, purified and immobilized on
glutathione-agarose beads. They were then incubated with radiolabelled
BRF that had been translated in vitro by using a reticulocyte lysate.
Proteins that remained bound to the beads after extensive washing were resolved by SDS-PAGE and then visualized by autoradiography (Fig. 3). Beads that carry GST-p107 or GST-p130
were found to retain BRF with an efficiency that is comparable to the
binding obtained by using GST-RB. This effect is largely dependent on
the presence of pocket protein sequences, since beads carrying an equal
amount of GST alone retained only background levels of BRF. The data suggest that each of the known pocket proteins can associate with the
BRF subunit of human TFIIIB. The interaction with BRF may be direct,
but we cannot exclude an involvement of other proteins that are present
in the reticulocyte lysate.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 3.
The BRF subunit of TFIIIB binds to recombinant RB, p107,
and p130. Reticulocyte lysate containing in vitro-translated BRF was
incubated in the presence of glutathione beads carrying equal amounts
of GST (lane 2), GST-RB (lane 3), GST-p107 (lane 4), or GST-p130 (lane
5). Proteins retained after extensive washing were resolved on an
SDS-7.8% polyacrylamide gel and then visualized by autoradiography.
Lane 1 shows 10% of the input reticulocyte lysate containing in
vitro-translated BRF. The truncated species of ~50 kDa that appears
in lane 1 is likely the result of degradation or internal initiation.
|
|
Endogenous p107 and p130 associate with the BRF subunit of
TFIIIB.
Immunoprecipitation experiments were carried out to test
whether BRF also interacts with endogenous cellular p107 and p130. Radiolabelled BRF was mixed with a HeLa cell extract that contains each
of the pocket proteins in a wild-type state. The mixture was then
immunoprecipitated by using a range of different antibodies immobilized
on protein A beads, and the precipitates were examined for the presence
of BRF by SDS-PAGE and autoradiography (Fig. 4). Antisera specific for RB, p107, and
p130 were each found to coprecipitate readily detectable amounts of
BRF. This effect is specific, since it was not observed by using a
control antiserum against the TAFI48 subunit of the Pol I
factor SL1. Similar results were obtained with alternative antisera
specific for the pocket proteins (35).

View larger version (42K):
[in this window]
[in a new window]
|
FIG. 4.
The BRF subunit of TFIIIB coimmunoprecipitates with
endogenous RB, p130, and p107. Reticulocyte lysate (15 µl) containing
in vitro-translated BRF was immunoprecipitated (IP) in the presence of
150 µg of HeLa whole-cell extract by using anti-RB antibody C-15
(lane 2), anti-p107 antibody C-18 (lane 3), anti-p130 antibody C-20
(lane 4), or anti-TAFI48 antibody M-19 (lane 5). Proteins
retained after extensive washing were resolved on an SDS-7.8%
polyacrylamide gel and then visualized by autoradiography. Lane 1 shows
10% of the input reticulocyte lysate containing in vitro-translated
BRF.
|
|
Immunoprecipitations were also carried out to test whether endogenous
TFIIIB can be found in association with endogenous p107
and p130. HeLa
cell extracts containing wild-type pocket proteins
were subjected to
immunoprecipitation with a range of antibodies
immobilized on protein A
beads; the precipitated material was
then resolved by SDS-PAGE and
probed for the presence of BRF by
Western blotting (Fig.
5A). Antibodies that specifically
recognize
either RB, p107, or p130 were each found to coprecipitate
BRF.
In contrast, no BRF was detected in immunoprecipitates obtained
with a control antibody against the TAF
I48 subunit of SL1.
The
presence of BRF in the material that coprecipitated with the pocket
proteins was confirmed by using a second antiserum raised against
a
different region of the BRF polypeptide (
35). As an
additional
test of specificity, we examined whether the Pol III factor
TFIIIC2
could also be coprecipitated with the various pocket proteins.
However, the

subunit of TFIIIC2 was not detected in
immunoprecipitates
obtained with antisera specific for RB, p107, or
p130 (
35).
We conclude that the association observed between
endogenous TFIIIB
and the endogenous pocket proteins is a specific
phenomenon.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Endogenous pocket proteins coimmunoprecipitate
specifically with endogenous TFIIIB. (A) HeLa cell extract (150 µg)
was immunoprecipitated (IP) by using anti-p107 antibody C-18 (lane 1),
anti-TAFI48 antibody M-19 (lanes 2 and 4), anti-RB antibody
C-15 (lane 3), and anti-p130 antibody C-20 (lane 5). Precipitated
material was resolved on an SDS-7.8% polyacrylamide gel and then
analyzed by Western blotting with anti-BRF antiserum 128. (B) HeLa cell
extract (150 µg) was immunoprecipitated by using anti-BRF antiserum
128 (lane 1) or preimmune serum (lane 2). Precipitated material was
resolved on an SDS-7.8% polyacrylamide gel and then analyzed by
Western blotting with anti-p107 antibody SD9. (C) HeLa cell extract
(150 µg) was immunoprecipitated by using anti-BRF antiserum 128 (lane
2) or the corresponding preimmune serum (lane 1). Precipitated material
was resolved on an SDS-7.8% polyacrylamide gel and then analyzed by
Western blotting with anti-Rb2 antibody against p130.
|
|
We also performed the converse experiment, in which the
immunoprecipitations were carried out by using a BRF antiserum or
the
corresponding preimmune control, and the coprecipitated material
was
probed for the presence of pocket proteins by Western blotting
with
monoclonal antibodies. Both p107 (Fig.
5B) and p130 (Fig.
5C) could be
readily detected in immunoprecipitates obtained with
the BRF antiserum,
but not with the preimmune control. The association
of endogenous
pocket proteins with endogenous TFIIIB has been
confirmed by using two
different antibodies against p107, two
different antibodies against
p130, and two different antibodies
against BRF (
35). In
serial immunodepletion experiments, we
have found up to ~30% of the
endogenous BRF in complexes with
these pocket proteins (
35).
However, this figure may vary considerably
according to cell type and
growth
conditions.
We have shown previously that a population of endogenous RB molecules
copurifies consistently with TFIIIB during chromatography
of cell
extracts. This cofractionation is strongly suggestive
of a stable
interaction. We tested whether the same is true of
p107 and p130.
Fractions containing various components of the
Pol III transcription
apparatus were probed for p107 by Western
blotting with a monoclonal
antibody (Fig.
6A). p107 was readily
detected in fractions containing TFIIIB that had been partially
purified by a combination of a phosphocellulose step and a Q-Sepharose
gradient (lane 1) or alternatively by a combination of phosphocellulose
and DEAE-Sephadex steps (lane 4). In contrast, p107 was not found
to
copurify with either Pol III or TFIIIC2 (lanes 2 and 3). p130
was also
detected in these TFIIIB fractions, but not in the fractions
containing
partially purified Pol III or TFIIIC2 (
4). As a
further test
for a stable interaction, we examined whether endogenous
p107 and p130
would cofractionate with TFIIIB during gradient
chromatography on
heparin-Sepharose. A phosphocellulose fraction
containing TFIIIB was
applied to a heparin-Sepharose column, and
the bound proteins were
eluted with a linear salt gradient. Individual
fractions were then
probed for the presence of TFIIIB (Fig.
6B,
upper panel) and p130 (Fig.
6B, lower panel). Both TFIIIB and
p130 were found to peak in fractions
20 to 22 and then tail off
sharply. Thus, p130 cofractionates closely
with TFIIIB on a heparin-Sepharose
salt gradient. The same was found to
be true of p107, and the
results were confirmed by using alternative
antisera against both
pocket proteins (
1). This consistent
cofractionation, along
with the coimmunoprecipitation data, suggests
that endogenous
TFIIIB associates stably and specifically with
endogenous p107
and p130.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
A population of endogenous p107 and p130 molecules
cofractionate with endogenous TFIIIB. (A) Fractionated factors (20 µl), as indicated, were resolved on an SDS-7.8% polyacrylamide gel
and then analyzed by Western immunoblotting with anti-p107 antibody
SD9. The TFIIIB fractions in lanes 1 and 4 were QS-PC-B (10.5 µg) and
A25(0.15) (1.6 µg), respectively. Lane 2 contained affinity-purified
TFIIIC2 (3.8 µg). The Pol III fraction in lane 3 was A25(1.0) (2.2 µg). (B) p130 cofractionates with TFIIIB during gradient
chromatography of a PC-B fraction on heparin-Sepharose. The upper panel
shows TFIIIB activity of individual fractions, and the lower panel
shows the p130 content of the same fractions. Fraction numbers are
indicated. SM, starting material; FT, flowthrough. TFIIIB activity was
assayed by using 4 µl of the indicated fraction, 2 µl of PC-C, and
250 ng of pVAI; after 15 min of incubation at 30°C,
nucleotides were added to assay transcription. p130 content was assayed
by using 15 µl of the indicated fractions, which were resolved on an
SDS-7.8% polyacrylamide gel and then analyzed by Western
immunoblotting with anti-Rb2 antibody specific for p130.
|
|
Pol III transcription is stimulated in vivo by the inactivation of
endogenous p107 and p130.
The E7 oncoprotein of human
papillomavirus 16 has been shown to bind to the pocket proteins and
prevent them from interacting with some of their cellular targets
(11, 28, 37). Transfection of NIH 3T3 cells with an
expression vector encoding wild-type E7 leads to a substantial increase
in the levels of Pol III transcription of a cotransfected
VAI gene (Fig. 7A). In
contrast, no stimulation is observed with E7 mutant
21-35, which is
unable to bind to any of the pocket proteins due to a deletion of
residues 21 to 35 (20). This suggests that E7 is activating
Pol III transcription by overcoming the repressive effects of the
endogenous pocket proteins, all of which are functional in these
fibroblasts. In order to determine whether p107 and p130 contribute to
this repression, we made use of E7 mutant GLY26, which carries a single
residue substitution at position 26; this mutant is unable to interact with RB, but retains its capacity to bind p107 and p130
(20). The GLY26 mutant was found to stimulate
VAI transcription, which suggests that p107 and/or p130 is
involved in repressing TFIIIB in these cells. However, endogenous RB
appears to make the principal contribution to this repression, since
the activation obtained with GLY26 is only 27% of that observed with
wild-type E7. It is important to note that each of these E7 constructs
is expressed at comparable levels (20). The results suggest
that Pol III transcription in this fibroblast cell line is subject to
repression not only by RB, but also by p107 and/or p130.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 7.
Transfected HPV E7 releases TFIIIB from repression by
pocket proteins in vivo. (A) NIH 3T3 cells were transfected with
pVAI (2 µg), pCAT (2 µg), and 6 µg of empty vector
(lane 1), or vector encoding wild-type (WT) E7 (lane 2), 21-35
mutant E7 (lane 3), or GLY26 mutant E7 (lane 4). The values shown for
VAI have been normalized to the levels of CAT expression to
correct for transfection efficiency and are given relative to the value
obtained for the vector control (arbitrarily designated 1). (B) SAOS2
cells were transfected with pVAI (2 µg), pCAT (2 µg),
and 6 µg of empty vector (lane 1) or vector encoding wild-type E7
(lane 2), 21-35 mutant E7 (lane 3), or GLY26 mutant E7 (lane 4).
The values shown for VAI have been normalized to the levels
of CAT expression to correct for transfection efficiency and are given
relative to the value obtained for the vector control (arbitrarily
designated 1).
|
|
The effect of E7 on Pol III transcription was also examined in SAOS2
cells, which contain wild-type p107 and p130 but only
a nonfunctional
truncated mutant form of RB (
34). Wild-type
E7 was found to
stimulate VA
I transcription, and this was again
due to
pocket protein binding, since the

21-35 mutant had very
little
effect (Fig.
7B). The level of activation was much less
than in NIH 3T3
cells, presumably due to the lack of functional
RB; untransfected SAOS2
cells have been shown previously to have
very high levels of Pol III
activity (
43). Unlike the situation
in NIH 3T3 cells, the
GLY26 mutant was no less efficient than
wild-type E7 in stimulating
VA
I transcription when transfected
into SAOS2 cells. This
is consistent with the absence of functional
RB in this osteosarcoma
line and the ability of GLY26 to bind
efficiently to p107 and p130
(
20). Taken together with our evidence
for an association
with TFIIIB, these results suggest that endogenous
p107 and/or p130
contributes to the repression of Pol III transcription
in at least some
mammalian cell
types.
Pol III activity is deregulated in fibroblasts derived from p107
p130 double knockout mice.
Specific gene disruption provides a
more direct method of investigating the roles of endogenous pocket
proteins. We compared the Pol III activities of MEFs from
p107
/
p130
/
double knockout mice with those of matched heterozygotes expressing p107 and p130 (wild-type cells of the same genetic background were not
available). Northern blot analysis was used to determine the levels of
a Pol III transcript derived from the B2 middle repetitive gene family
in RNA extracted from these MEFs (Fig. 8,
upper panel). When growing rapidly in the presence of 10% serum, the
p107 p130 null cells showed only slightly elevated B2 transcript levels
compared with the corresponding MEFs expressing a full complement of
pocket proteins (lanes 2 and 4, respectively). However, a more
substantial difference was observed following serum withdrawal. When
made quiescent through serum deprivation, the double knockout cells
expressed B2 RNA at approximately twice the level of the matched
heterozygotes (lanes 1 and 3, respectively). This effect was specific,
since knockout of p107 and p130 did not alter the abundance of a Pol II
transcript encoding acidic ribosomal phosphoprotein P0 (Fig. 8, lower
panel). It has been demonstrated previously that p107 p130 null MEFs
are not compromised in their ability to exit the cell cycle following
serum withdrawal (16). This was confirmed in the present
experiments by measuring [3H]thymidine incorporation as
an indicator of DNA synthesis (26). Although the p107 p130
double knockouts are made quiescent in an apparently normal fashion,
they are compromised in their ability to down-regulate Pol III. These
observations provide additional evidence that endogenous p107 and/or
p130 makes a significant contribution to the control of Pol III
transcription in vivo.

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 8.
p107 p130 double knockout fibroblasts display a specific
increase in the expression of Pol III transcripts following serum
withdrawal. Results represent Northern blot analysis of total RNA (10 µg) extracted from p107 /
p130 / double knockout MEFs (lanes 1 and 2)
or matched p107+/
p130+/ heterozygotes (lanes 3 and 4) that were
actively growing in 10% serum (lanes 2 and 4) or made quiescent by
culture for 24 h in 0.5% serum (lanes 1 and 3). The upper panel
shows the blot probed with a B2 gene, and the lower panel shows the
same blot that has been stripped and reprobed with the ARPP P0 gene.
|
|
 |
DISCUSSION |
The data presented in this article suggest that the RB-related
pocket proteins p107 and p130 can associate with TFIIIB and repress Pol
III transcription both in vitro and in vivo. Expression of the
VAI gene in transiently transfected cells can be inhibited by either p107 or p130. These pocket proteins will also repress a range
of Pol III templates when added to cell extracts. These regulatory
effects can be explained by a stable and specific interaction with
TFIIIB. Thus, pull-down assays reveal that the BRF subunit of TFIIIB
will associate with p107 and p130 that have been expressed in bacteria
as GST fusion proteins. Furthermore, endogenous BRF can be
coimmunoprecipitated with endogenous p107 and p130. A significant increase in Pol III transcription is observed in vivo when the E7
oncoprotein is used to neutralize the endogenous p107 and p130. Furthermore, targeted disruption of the genes encoding p107 and p130
results in a specific increase in Pol III transcript levels in
quiescent MEFs. We conclude that these pocket proteins are likely to
constitute physiologically significant regulators of class III gene expression.
Analyses of several deletion and substitution mutations have shown that
the pocket domain is required for RB to regulate Pol III activity both
in vitro and in vivo (5, 43). This conclusion is reinforced
by the effect observed here with E7, a protein which has been shown to
bind to the pocket by crystallographic analysis (24). Since
the pocket domain is the principal region of homology between RB and
its relatives p107 and p130, it is not unexpected that all three of
these proteins can interact with TFIIIB. Nevertheless, this was by no
means a foregone conclusion, since there is substantial sequence
divergence, even in the pocket region (12). Furthermore, many of the genes regulated in murine fibroblasts by p107 and p130 are
different from the set of targets that are controlled by RB
(16).
Of the three known pocket proteins, RB appears to play the dominant
role in controlling Pol III transcription in cycling murine fibroblasts. Thus, VAI expression in growing NIH 3T3 cells
was stimulated much more strongly by wild-type E7 than by the GLY26 mutant that only targets p107 and p130. Furthermore, knockout of RB
causes a substantial increase in Pol III transcription in growing MEFs
(43), whereas knockout of p107 and p130 has little effect
under the same circumstances. Hurford et al. (16) have shown
previously that growing p107
/
p130
/
MEFs upregulate RB levels; this may
explain why there is little effect on B2 gene expression, since
overproduction of RB may compensate for the loss of p107 and p130.
However, the upregulation of RB in p107
/
p130
/
MEFs is largely restricted to cycling
cells and is not observed following serum starvation (16);
accordingly, the effect of these pocket proteins on Pol III activity is
revealed when the double knockouts become quiescent.
RB, p107, and p130 share the ability to inhibit cell growth (7,
30, 44, 45). Although unique regulatory functions may contribute
to this capability (44), it seems likely that growth arrest
by these homologous proteins involves the control of a number of common
cellular targets. Since rapid growth requires high rates of synthesis
of tRNA and rRNA, it has been suggested that the repression of Pol III
transcription may contribute to the growth control function of RB
(15, 21, 29, 39). A similar argument can now be applied to
p107 and p130.
 |
ACKNOWLEDGMENTS |
We thank Peter Whyte and Xavier Mayol for pocket protein
expression constructs, Roger Watson and Karen Vousden for E7 expression vectors, Fred Dick for ARPP P0, and Rene Bernards for MEFs.
This work was funded by project grant CO5766 to R.J.W. from the
Biotechnology and Biological Sciences Research Council and by project
grant 98-46 to R.J.W. from the Association for International Cancer
Research. R.J.W. is a Jenner Research Fellow of the Lister Institute of
Preventive Medicine.
J.E.S. and S.J.A. were supported by studentships from the Biotechnology
and Biological Sciences Research Council and the Medical Research
Council, respectively.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institute of
Biomedical and Life Sciences, Division of Biochemistry and Molecular
Biology, Davidson Building, University of Glasgow, Glasgow G12 8QQ,
United Kingdom. Phone: 0141-330-4628. Fax: 0141-330-4620. E-mail:
rwhite{at}udcf.gla.ac.uk.
 |
REFERENCES |
| 1.
| Allison, S. J., and R. J. White.
Unpublished observations.
|
| 2.
|
Alzuherri, H. M., and R. J. White.
1998.
Regulation of a TATA-binding protein-associated factor during cellular differentiation.
J. Biol. Chem.
273:17166-17171[Abstract/Free Full Text].
|
| 3.
|
Cairns, C. A., and R. J. White.
1998.
p53 is a general repressor of RNA polymerase III transcription.
EMBO J.
17:3112-3123[Medline].
|
| 4.
| Cairns, C. A., and R. J. White.
Unpublished observations.
|
| 5.
|
Chu, W.-M.,
Z. Wang,
R. G. Roeder, and C. W. Schmid.
1997.
RNA polymerase III transcription repressed by Rb through its interactions with TFIIIB and TFIIIC2.
J. Biol. Chem.
272:14755-14761[Abstract/Free Full Text].
|
| 6.
|
Clarke, A. R.,
E. R. Maandag,
M. van Roon,
N. M. T. van der Lugt,
M. van der Valk,
M. L. Hooper,
A. Berns, and H. te Riele.
1992.
Requirement for a functional Rb-1 gene in murine development.
Nature
359:328-330[Medline].
|
| 7.
|
Claudio, P. P.,
C. M. Howard,
A. Baldi,
A. De Luca,
Y. Fu,
G. Condorelli,
Y. Sun,
N. Colburn,
B. Calabretta, and A. Giordano.
1994.
p130/Rb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p107.
Cancer Res.
54:5556-5560[Abstract/Free Full Text].
|
| 8.
|
Cobrinik, D.,
M. H. Lee,
G. Hannon,
G. Mulligan,
R. T. Bronson,
N. Dyson,
E. Harlow,
D. Beach,
R. A. Weinberg, and T. Jacks.
1996.
Shared role of the pRB-related p130 and p107 proteins in limb development.
Genes Dev.
10:1633-1644[Abstract/Free Full Text].
|
| 9.
|
Corbeil, H. B.,
P. Whyte, and P. E. Branton.
1995.
Characterization of transcription factor E2F complexes during muscle and neuronal differentiation.
Oncogene
11:909-920[Medline].
|
| 10.
|
Dyson, N.
1998.
The regulation of E2F by pRB-family proteins.
Genes Dev.
12:2245-2262[Free Full Text].
|
| 11.
|
Dyson, N.,
P. M. Howley,
K. Munger, and E. Harlow.
1989.
The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.
Science
243:934-937[Abstract/Free Full Text].
|
| 12.
|
Ewen, M. E.,
Y. Xing,
J. B. Lawrence, and D. M. Livingston.
1991.
Molecular cloning, chromosomal mapping and expression of the cDNA for p107, a retinoblastoma gene product-related protein.
Cell
66:1155-1164[Medline].
|
| 13.
|
Grana, X.,
J. Garriga, and X. Mayol.
1998.
Role of the retinoblastoma protein family, pRB, p107 and p130 in the negative control of cell growth.
Oncogene
17:3365-3383[Medline].
|
| 14.
|
Hernandez, N.
1993.
TBP, a universal eukaryotic transcription factor?
Genes Dev.
7:1291-1308[Free Full Text].
|
| 15.
|
Herwig, S., and M. Strauss.
1997.
The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis.
Eur. J. Biochem.
246:581-601[Medline].
|
| 16.
|
Hurford, R. K.,
D. Cobrinik,
M.-H. Lee, and N. Dyson.
1997.
pRB and p107/p130 are required for the regulated expression of different sets of E2F responsive genes.
Genes Dev.
11:1447-1463[Abstract/Free Full Text].
|
| 17.
|
Jacks, T.,
A. Fazeli,
E. M. Schmitt,
R. T. Bronson,
M. A. Goodell, and R. A. Weinberg.
1992.
Effects of an Rb mutation in the mouse.
Nature
359:295-300[Medline].
|
| 18.
|
Kassavetis, G. A.,
B. R. Braun,
L. H. Nguyen, and E. P. Geiduschek.
1990.
S. cerevisiae TFIIIB is the transcription initiation factor proper of RNA polymerase III, while TFIIIA and TFIIIC are assembly factors.
Cell
60:235-245[Medline].
|
| 19.
|
Khoo, B.,
B. Brophy, and S. P. Jackson.
1994.
Conserved functional domains of the RNA polymerase III general transcription factor BRF.
Genes Dev.
8:2879-2890[Abstract/Free Full Text].
|
| 20.
|
Lam, E. W.-F.,
J. D. H. Morris,
R. Davies,
T. Crook,
R. J. Watson, and K. H. Vousden.
1994.
HPV16 E7 oncoprotein deregulates B-myb expression: correlation with targeting of p107/E2F complexes.
EMBO J.
13:871-878[Medline].
|
| 21.
|
Larminie, C. G. C.,
H. M. Alzuherri,
C. A. Cairns,
A. McLees, and R. J. White.
1998.
Transcription by RNA polymerases I and III: a potential link between cell growth, protein synthesis and the retinoblastoma protein.
J. Mol. Med.
76:94-103[Medline].
|
| 22.
|
Larminie, C. G. C.,
C. A. Cairns,
R. Mital,
K. Martin,
T. Kouzarides,
S. P. Jackson, and R. J. White.
1997.
Mechanistic analysis of RNA polymerase III regulation by the retinoblastoma protein.
EMBO J.
16:2061-2071[Medline].
|
| 23.
|
Lee, E. Y.-H. P.,
C.-Y. Chang,
N. Hu,
Y.-C. J. Wang,
C.-C. Lai,
K. Herrup,
W.-H. Lee, and A. Bradley.
1992.
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis.
Nature
359:288-294[Medline].
|
| 24.
|
Lee, J.-O.,
A. A. Russo, and N. P. Pavletich.
1998.
Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7.
Nature
391:859-865[Medline].
|
| 25.
|
Manley, J. L.,
A. Fire,
A. Cano,
P. A. Sharp, and M. L. Gefter.
1980.
DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract.
Proc. Natl. Acad. Sci. USA
77:3855-3859[Abstract/Free Full Text].
|
| 26.
| McLees, A., and R. J. White. Unpublished
observations.
|
| 27.
|
Mulligan, G., and T. Jacks.
1998.
The retinoblastoma gene family: cousins with overlapping interests.
Trends Genet.
14:223-229[Medline].
|
| 28.
|
Munger, K.,
B. A. Werness,
N. Dyson,
W. C. Phelps,
E. Harlow, and P. M. Howley.
1989.
Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumour suppressor gene product.
EMBO J.
8:4099-4105[Medline].
|
| 29.
|
Nasmyth, K.
1996.
Another role rolls in.
Nature
382:28-29[Medline].
|
| 30.
|
Qin, X.,
T. Chittenden,
D. M. Livingston, and W. G. Kaelin.
1992.
Identification of a growth suppression domain within the retinoblastoma gene product.
Genes Dev.
6:953-964[Abstract/Free Full Text].
|
| 31.
|
Rigby, P. W. J.
1993.
Three in one and one in three: it all depends on TBP.
Cell
72:7-10[Medline].
|
| 32.
|
Segall, J.,
T. Matsui, and R. G. Roeder.
1980.
Multiple factors are required for the accurate transcription of purified genes by RNA polymerase III.
J. Biol. Chem.
255:11986-11991[Abstract/Free Full Text].
|
| 33.
|
Shen, Y.,
M. Igo,
P. Yalamanchili,
A. J. Berk, and A. Dasgupta.
1996.
DNA binding domain and subunit interactions of transcription factor IIIC revealed by dissection with poliovirus 3C protease.
Mol. Cell. Biol.
16:4163-4171[Abstract].
|
| 34.
|
Shew, J.-Y.,
B. T.-Y. Lin,
P.-L. Chen,
B. Y. Tseng,
T. L. Yang-Feng, and W.-H. Lee.
1990.
C-terminal truncation of the retinoblastoma gene product leads to functional inactivation.
Proc. Natl. Acad. Sci. USA
87:6-10[Abstract/Free Full Text].
|
| 35.
| Sutcliffe, J. E., and R. J. White.
Unpublished observations.
|
| 36.
|
Taya, Y.
1997.
RB kinases and RB-binding proteins: new points of view.
Trends Biochem. Sci.
22:14-17[Medline].
|
| 37.
|
Vousden, K. H.
1995.
Regulation of the cell cycle by viral oncoproteins.
Semin. Cancer Biol.
6:109-116[Medline].
|
| 38.
|
Werner, M.,
N. Chaussivert,
I. M. Willis, and A. Sentenac.
1993.
Interaction between a complex of RNA polymerase III subunits and the 70-kDa component of transcription factor IIIB.
J. Biol. Chem.
268:20721-20724[Abstract/Free Full Text].
|
| 39.
|
White, R. J.
1997.
Regulation of RNA polymerases I and III by the retinoblastoma protein: a mechanism for growth control?
Trends Biochem. Sci.
22:77-80[Medline].
|
| 40.
|
White, R. J.
1998.
RNA polymerase III transcription.
Springer-Verlag, Berlin, Germany.
|
| 41.
|
White, R. J.,
T. M. Gottlieb,
C. S. Downes, and S. P. Jackson.
1995.
Mitotic regulation of a TATA-binding-protein-containing complex.
Mol. Cell. Biol.
15:1983-1992[Abstract].
|
| 42.
|
White, R. J.,
D. Stott, and P. W. J. Rigby.
1989.
Regulation of RNA polymerase III transcription in response to F9 embryonal carcinoma stem cell differentiation.
Cell
59:1081-1092[Medline].
|
| 43.
|
White, R. J.,
D. Trouche,
K. Martin,
S. P. Jackson, and T. Kouzarides.
1996.
Repression of RNA polymerase III transcription by the retinoblastoma protein.
Nature
382:88-90[Medline].
|
| 44.
|
Woo, M. S.-A.,
I. Sánchez, and B. D. Dynlacht.
1997.
p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity.
Mol. Cell. Biol.
17:3566-3579[Abstract].
|
| 45.
|
Zhu, L.,
S. van den Heuvel,
K. Helin,
A. Fattaey,
M. Ewen,
D. Livingston,
N. Dyson, and E. Harlow.
1993.
Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein.
Genes Dev.
7:1111-1125[Abstract/Free Full Text].
|
Molecular and Cellular Biology, June 1999, p. 4255-4261, Vol. 19, No. 6
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hirsch, H. A., Jawdekar, G. W., Lee, K.-A., Gu, L., Henry, R. W.
(2004). Distinct Mechanisms for Repression of RNA Polymerase III Transcription by the Retinoblastoma Tumor Suppressor Protein. Mol. Cell. Biol.
24: 5989-5999
[Abstract]
[Full Text]
-
Felton-Edkins, Z. A., White, R. J.
(2002). Multiple Mechanisms Contribute to the Activation of RNA Polymerase III Transcription in Cells Transformed by Papovaviruses. J. Biol. Chem.
277: 48182-48191
[Abstract]
[Full Text]
-
Ciarmatori, S., Scott, P. H., Sutcliffe, J. E., McLees, A., Alzuherri, H. M., Dannenberg, J.-H., te Riele, H., Grummt, I., Voit, R., White, R. J.
(2001). Overlapping Functions of the pRb Family in the Regulation of rRNA Synthesis. Mol. Cell. Biol.
21: 5806-5814
[Abstract]
[Full Text]
-
Sutcliffe, J. E., Brown, T. R. P., Allison, S. J., Scott, P. H., White, R. J.
(2000). Retinoblastoma Protein Disrupts Interactions Required for RNA Polymerase III Transcription. Mol. Cell. Biol.
20: 9192-9202
[Abstract]
[Full Text]
-
Schramm, L., Pendergrast, P. S., Sun, Y., Hernandez, N.
(2000). Different human TFIIIB activities direct RNA polymerase III transcription from TATA-containing and TATA-less promoters. Genes Dev.
14: 2650-2663
[Abstract]
[Full Text]
-
Li, Y., Moir, R. D., Sethy-Coraci, I. K., Warner, J. R., Willis, I. M.
(2000). Repression of Ribosome and tRNA Synthesis in Secretion-Defective Cells Is Signaled by a Novel Branch of the Cell Integrity Pathway. Mol. Cell. Biol.
20: 3843-3851
[Abstract]
[Full Text]
-
Paule, M. R., White, R. J.
(2000). SURVEY AND SUMMARY Transcription by RNA polymerases I and III. Nucleic Acids Res
28: 1283-1298
[Abstract]
[Full Text]
-
Scott, P. H., Cairns, C. A., Sutcliffe, J. E., Alzuherri, H. M., McLees, A., Winter, A. G., White, R. J.
(2001). Regulation of RNA Polymerase III Transcription during Cell Cycle Entry. J. Biol. Chem.
276: 1005-1014
[Abstract]
[Full Text]